Table 3 Significant Spearman rank correlations between tumor PSA score and Ki67 labeling index with other previously measured variables of prognostic significance (see Table 2 for references) describing tumor and surrounding normal prostate tissue (TINT) [37]
Correlation coefficient for tumor PSA score | Correlation coefficient for tumor Ki67 labeling index | |
|---|---|---|
Clinical markers | ||
Gleason score | −0.54c (n = 346) | 0.50c (n = 389) |
Tumor stage | −0.41c (n = 339) | 0.42c (n = 382) |
M stage | −0.31c (n = 272) | 0.33c (n = 301) |
Cancer (%) | −0.47c (n = 346) | 0.45c (n = 389) |
Overall survival | 0.21c (n = 346) | −0.15b (n = 389) |
Tumor markers | ||
Ki67 (%) | −0.46c (n = 331) | |
pEGF-R score | −0.21b (n = 252) | 0.28c (n = 293) |
pAkt score | −0.31c (n = 255) | 0.36c (n = 278) |
ErbB2 score | −0.29c (n = 307) | 0.29c (n = 350) |
Vascular density (%) | −0.24c (n = 330) | 0.28c (n = 381) |
Hyaluronic acid score (stroma) | −0.18b (n = 334) | 0.27c (n = 384) |
Mast cell density (%) | 0.21c (n = 322) | −0.13a (n = 362) |
Androgen receptor (%) (stroma) | 0.17b (n = 329) | −0.17b (n = 373) |
PDGFR-beta (stroma) (37) | −0.15a (n = 248) | 0.21c (n = 283) |
Caveolin-1 score (stroma) | 0.25c (n = 326) | −0.25c (n = 370) |
CD163 (%) | −0.24b (n = 177) | |
Erg (positive or not) | −0.39c (n = 315) | 0.32c (n = 350) |
TINT markers | ||
Ki67 | 0.17b (n = 360) | |
pEGF-R | −0.19b (n = 244) | 0.25c (n = 284) |
PDGFR-beta (stroma) (37) | −0.13a (n = 302) | 0.15b (n = 344) |
Hyaluronic acid score (stroma) | −0.14a (n = 318) | 0.14b (n = 363) |
Mast cell density (%) | −0.22c (n = 299) | |
Caveolin-1 score (stroma) | −0.11a (n = 352) | |
Erg (positive or not) | 0.16b (n = 331) | |
